Such a merger would’ve faced a plethora of antitrust issues; however, investors evidently expect MON to re-emerge or another suitor—such as DD, DOW, BASF, or Bayer—to show up.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”